

SUPPLEMENTARY TABLE S2. RISK FOR HEPATIC STEATOSIS PROGRESSION
AFTER HEPATITIS C VIRUS (HCV) ERADICATION

<i>Patient characteristics (N=138)</i>	<i>OR for ΔCAP ≤ +10%</i>	<i>p</i>	<i>aOR for ΔCAP ≤ +10%</i>	<i>p</i>
Epidemiological characteristics				
Sex				
Male	1.79 (0.73–4.37)	0.204		
Age (per 5 years)	0.83 (0.70–1.00)	0.047		
Ethnicity				
Caucasian	0.26 (0.05–1.47)	0.127		
African American (N=4), Hispanic (N=0), or Asian (N=2)	3.87 (0.68–21.92)	0.127		
Transmission				
MSM	2.99 (1.43–6.23)	0.003	1.77 (0.66–4.75)	0.257
PWID	0.47 (0.23–0.97)	0.041		
Others	0.59 (0.22–1.61)	0.305		
Weight (per 5 kg)	0.99 (0.88–1.11)	0.847		
BMI (kg/m ²)	0.98 (0.90–1.06)	0.589		
DM	1.39 (0.30–6.46)	0.678		
Hypertension	1.63 (0.52–5.17)	0.403		
PNPLA3				
CC, GC, GG	1.12 (0.58–2.15)	0.733		
Laboratory parameters				
Platelet count (G/L) per 10	1.05 (1.00–1.11)	0.040		
Prothrombin time (%)	1.07 (0.90–1.27)	0.474		
Bilirubin (mg/dL)	0.88 (0.39–1.95)	0.747		
Albumin (g/dL)	1.72 (1.04–2.85)	0.034		
AST (U/L)	1.00 (0.96–1.04)	0.990		
ALT (U/L)	1.01 (0.99–1.03)	0.434		
GGT (U/L)	1.01 (0.99–1.03)	0.287		
TG (per 10 mg/dL)	1.00 (0.95–1.05)	0.972		
TCHOL (per 10 mg/dL)	1.07 (0.98–1.16)	0.153		
HDL (per 10 mg/dL)	0.93 (0.75–1.15)	0.498		
LDL (per 10 mg/dL)	1.18 (1.05–1.34)	0.007	1.18 (1.02–1.35)	0.022
HOMA-IR	1.05 (1.00–1.10)	0.054		
HIV infection parameters				
Time since diagnosis of HIV (years)	0.96 (0.92–1.00)	0.028	1.02 (0.95–1.09)	0.614
CD4 ⁺ T lymphocyte count	1.03 (0.97–1.10)	0.321		
HIV-RNA <50 copies/mL	0.87 (0.33–2.27)	0.770		
HIV-RNA <400 copies/mL	1.10 (0.26–4.60)	0.899		
ART before HCV treatment				
PI	0.17 (0.06–0.51)	0.002	0.21 (0.06–0.76)	0.017
N(t)RTI	4.20 (0.50–35.19)	0.186		
NNRTI	2.37 (1.11–4.99)	0.025		
INSTI	1.22 (0.61–2.47)	0.572		
Time on ART (years)	0.93 (0.89–0.98)	0.011	0.94 (0.88–1.00)	0.052
HCV infection parameters				
Time since diagnosis of HCV (years)	0.95 (0.91–0.98)	0.006		
HCV-RNA (log IU/mL)	0.54 (0.37–0.78)	0.001	0.57 (0.37–0.88)	0.011
HCV-GT				
1a	2.53 (1.22–5.24)	0.013		
1b	0.23 (0.05–1.05)	0.058		
2	0.00 (0-)	0.999		
3	0.73 (0.30–1.74)	0.477		
4	0.90 (0.29–2.79)	0.852		
Liver stiffness				
F0/F1 (<7.1 kPa)	2.03 (0.99–4.17)	0.054		
F2 (≥7.1 and <9.5 kPa)	1.00 (0.48–2.11)	0.993		
F3 (≥9.5 and <12.5 kPa)	0.69 (0.25–1.91)	0.472		
F4 (≥12.5 kPa)	0.35 (0.11–1.10)	0.073		
Steatosis				
S0 (<248 dB/m)	4.87 (1.88–12.63)	0.001		
≥S1 (≥248 dB/m)	0.21 (0.08–0.53)	0.001		

Bold *p* values denote statistical significance.

ALT, alanine transaminase; aOR, adjusted odds ratio; ART, antiretroviral therapy; AST, aspartate transaminase; BMI, body mass index; CAP, controlled attenuation parameter; DM, diabetes mellitus; GGT, gamma-glutamyl transpeptidase; GT, genotype; HCV, hepatitis C virus; HDL, high-density lipoprotein; HIV, human immunodeficiency virus; HOMA-IR, homeostasis model assessment for insulin resistance; INSTI, integrase inhibitor; LDL, low-density lipoprotein; MSM, men who have sex with men; NNRTI, non-nucleoside reverse-transcriptase inhibitor; N(t)RTI, nucleos(t)idic reverse transcriptase inhibitor; PI, protease inhibitor; PNPLA3, patatin-like phospholipase domain containing 3; PWID, people who inject drugs; TCHOL, total cholesterol; TG, triglyceride.